Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Earnings Winners And Losers: BSX, BCR, NUVA, NVCR

Executive Summary

Several big names in medtech announced their second-quarter sales and earnings in late July and early August. Here are some of the companies that impressed investors and others that raised some doubts.

Advertisement

Related Content

Abbott Becomes CRM Player Overnight By Completing St. Jude Deal
OUS Approvals Analysis: November Product Go-Aheads Headlined by LimFlow, Abbott, Creavo
NuVasive To Settle Medtronic Spinal Patent Suit
MNA ANALYSIS: Cardio And Ortho Billion-Buck Deals Headline Otherwise Slow Month
APPROVALS ANALYSIS: Big Month For Cardio Devices, But Down Overall
Bard, J&J Settle Mesh Cases
Mesh Lawsuit Claims Boston Scientific Smuggled Counterfeit Product Out Of China
NuVasive To Expands Global Presence, Pediatric Portfolio With Ellipse Buy
Spine Market: Pure Plays Continue to Grab Share
CLINICAL CORNER: Watchman Appears Cost-Effective, Neuromodulation Data From NANS; BTG’s PneumRx

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT103663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel